Drug Trial Radar · NCT06842186
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jan 31, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Wave Life Sciences USA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in adult with obesity, with or without Type 2 Diabetes (T2D and non-T2D, respectively). In addition, Part B includes two dose groups that will receive WVE-007 and tirzepatide in adults living with obesity and T2D.
Conditions
- Overweight and Obesity
Interventions
WVE-007Drug
Stereopure siRNA oligonucleotide
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants with treatment emergent adverse eventsTime frame: Day 1 through end of study
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Arensia Exploratory Medicine, Inc. USA
Phoenix, Arizona · Active not recruiting
Parexel International-EPCU Baltimore
Baltimore, Maryland · Recruiting
ARENSIA Research Clinic
Chisinau, Moldova · Recruiting
Arensia Clinics S.R.L.
Bucharest, Romania · Recruiting
Spitalul Clinic Judetean De Urgenta Cluj
Cluj-Napoca, Romania · Recruiting
Parexel International Early Phase Clinical Unit
Harrow, United Kingdom · Recruiting
Simbec-Orion Clinical Pharmacology
Merthyr Tydfil, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.